International Journal of COPD (Feb 2022)
Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study
Abstract
Chin-Hsiao Tseng1– 3 1Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; 3National Institute of Environmental Health Sciences, Zhunan, TaiwanCorrespondence: Chin-Hsiao Tseng, Tel/Fax +886 2 2388 3578, Email [email protected]: Pioglitazone’s effect on chronic obstructive pulmonary disease (COPD) has rarely been studied.Purpose: This retrospective observational study investigated whether the use of pioglitazone would affect the risk of COPD in patients with type 2 diabetes mellitus.Patients and Methods: The Taiwan’s National Health Insurance database was used to enroll 9487 matched pairs of ever users and never users of pioglitazone based on propensity score from a cohort of 350,536 patients. The enrolled patients had a new diagnosis of type 2 diabetes mellitus between 1999 and 2008 and were not having a diagnosis of COPD before January 1, 2009. They were then followed up for COPD, starting from January 1, 2009 until December 31, 2011. Diagnosis of COPD was based on the codes of 491 for chronic bronchitis and 492 for emphysema based on the International Classification of Diseases, Ninth Revision, Clinical Modification. Cox regression was used to estimate hazard ratios. The interactions between pioglitazone and COPD risk factors including pneumonia, pulmonary tuberculosis and tobacco abuse were also investigated.Results: In 9487 never users and 9487 ever users of pioglitazone, the case numbers of incident COPD were 359 and 295, respectively. The respective incidence rates of COPD were 1484.73 and 1167.61 per 100,000 person-years. The overall hazard ratio (95% confidence interval) for COPD that compared ever to never users was 0.778 (0.667– 0.908). The hazard ratios for the tertiles of cumulative duration of pioglitazone therapy (cutoffs: 19.6 months) to never users were 0.904 (0.729– 1.121), 0.727 (0.578– 0.914) and 0.715 (0.570– 0.896), respectively. No interactions between pioglitazone and COPD risk factors including pneumonia, pulmonary tuberculosis and tobacco abuse were noted.Conclusion: Pioglitazone use is associated with a significantly lower risk of COPD.Keywords: chronic bronchitis, emphysema, pharmacoepidemiological study, risk factors, Taiwan, thiazolidinediones
